[Drug flow. Good manufacturing practices, good clinical practices]

Area of Science:

• Pharmaceutical Science
• Clinical Research Quality Assurance

Context:

• The global drug development process is increasingly focused on quality improvement.
• Clinical trials are central to drug development and require stringent oversight.
• Ensuring the integrity and efficacy of investigational drugs is paramount.

Purpose:

• To outline methods for enhancing quality in the clinical trial drug development circuit.
• To present strategies at the intersection of Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP).
• To provide examples of quality improvement initiatives in drug development.

Summary:

• Quality enhancement strategies focus on strengthening controls, such as "jury" verification of drug resemblance in double-blind studies and computerized drug accountability systems.
• Improvements in "compliance with therapy at the site of investigation" are achieved through advanced methods like "intelligent" drug packaging and labeling.
• These integrated approaches aim to elevate the overall quality and reliability of clinical trial drug supply and administration.

Impact:

• Implementation of these quality-focused methods can lead to more reliable clinical trial outcomes.
• Enhanced controls and compliance contribute to the global advancement of safe and effective drug development.
• This approach supports the integrity of the drug development circuit, ensuring better therapeutic outcomes.